Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs

Fenghao Geng; Jianhui Chen; Shaokai Tang; Edouard I. Azzam; Jie Zhang; Shuyu Zhang

doi:10.1667/RADE-22-00058.1

Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs

Fenghao Geng, Jianhui Chen, Shaokai Tang, Edouard I. Azzam, Jie Zhang, Shuyu Zhang

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.

Original language	English (US)
Pages (from-to)	306-317
Number of pages	12
Journal	Radiation Research
Volume	198
Issue number	3
DOIs	https://doi.org/10.1667/RADE-22-00058.1
State	Published - Jul 14 2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

Biophysics
Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1667/RADE-22-00058.1

Cite this

@article{557a9327f32c48848a8036b966df95c7,

title = "Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs",

abstract = "COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.",

author = "Fenghao Geng and Jianhui Chen and Shaokai Tang and Azzam, {Edouard I.} and Jie Zhang and Shuyu Zhang",

note = "Funding Information: The authors would like to thank Qidong Zu (OE Biotech, Inc., Shanghai, China, http://www.oebiotech.com/) for assistance with the bioinformatics analysis of RNA-seq. This work is supported by the National Natural Science Foundation of China (82073477 and 31770909), Science Foundation for Distinguished Young Scholars of Shaanxi Province (2018JC-013) and Central Government Funds of Guiding Local Scientific and Technological Development for Sichuan Province (2021ZYD0073). Publisher Copyright: {\textcopyright} 2022 by Radiation Research Society. All rights of reproduction in any form reserved.",

year = "2022",

month = jul,

day = "14",

doi = "10.1667/RADE-22-00058.1",

language = "English (US)",

volume = "198",

pages = "306--317",

journal = "Radiation Research",

issn = "0033-7587",

publisher = "Radiation Research Society",

number = "3",

}

TY - JOUR

T1 - Additional Evidence for Commonalities between COVID-19 and Radiation Injury

T2 - Novel Insight into COVID-19 Candidate Drugs

AU - Geng, Fenghao

AU - Chen, Jianhui

AU - Tang, Shaokai

AU - Azzam, Edouard I.

AU - Zhang, Jie

AU - Zhang, Shuyu

N1 - Funding Information: The authors would like to thank Qidong Zu (OE Biotech, Inc., Shanghai, China, http://www.oebiotech.com/) for assistance with the bioinformatics analysis of RNA-seq. This work is supported by the National Natural Science Foundation of China (82073477 and 31770909), Science Foundation for Distinguished Young Scholars of Shaanxi Province (2018JC-013) and Central Government Funds of Guiding Local Scientific and Technological Development for Sichuan Province (2021ZYD0073). Publisher Copyright: © 2022 by Radiation Research Society. All rights of reproduction in any form reserved.

PY - 2022/7/14

Y1 - 2022/7/14

N2 - COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.

AB - COVID-19 is a challenge to biosecurity and public health. The speed of vaccine development lags behind that of virus evolution and mutation. To date, no agent has been demonstrated to be fully effective against COVID-19. Therefore, it remains of great urgency to rapidly develop promising therapeutic and diagnostic candidates. Intriguingly, mounting evidence hints at parallel etiologies between SARS-CoV-2 infection and radiation injury. Herein, from the perspectives of immunogenic pathway activation and metabolic alterations, we provide novel evidence of commonalities between these two pathological conditions based on the most recent findings. Since numerous agents have been developed to prevent or reverse radiation injury in the past 70 years to ensure nuclear safety, we also advocate investigating the promising function of radioprotectors and radiomitigators against COVID-19 in clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=85138125928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138125928&partnerID=8YFLogxK

U2 - 10.1667/RADE-22-00058.1

DO - 10.1667/RADE-22-00058.1

M3 - Review article

C2 - 35834824

AN - SCOPUS:85138125928

SN - 0033-7587

VL - 198

SP - 306

EP - 317

JO - Radiation Research

JF - Radiation Research

IS - 3

ER -

Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this